June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
The concept of a three-drug minimum for HIV therapy is rooted in a sequentialism that emerged with the dawning of antiretroviral treatment: one drug = nothing; two drugs = meh; three drugs = bingo! Over the years, in an effort to avoid peskier antire...
In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...
Researchers found that around 90% of participants who were switched to a dual drug regimen maintained a suppressed viral load over the course of the study.
Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...